Projected Impact of Pharmacogenomic Testing on Medications Beyond Antiplatelet Therapy in Percutaneous Coronary Intervention Patients

References

• US FDA . Table of pharmacogenomic biomarkers in drug labeling | FDA. (2019). https://www.fda.gov/drugs/science-research-drugs/table-pharmacogenomic-biomarkers-drug-labeling
   Google Scholar
• Relling MV , EvansWE. Pharmacogenomics in the clinic. Nature526(7573), 343–350 (2015).
   PubMed Web of Science ®Google Scholar
• Caudle K , KleinT , HoffmanJet al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab.15(2), 209–217 (2014).
   PubMed Web of Science ®Google Scholar
• Clinical Pharmacogenetics Implementation Consortium . Genes–drugs – CPIC. (2019). https://cpicpgx.org/genes-drugs/
   Google Scholar
• Ji Y , SkierkaJM , BlommelJHet al. Preemptive pharmacogenomic testing for precision medicine a comprehensive analysis of five actionable pharmacogenomic genes using next-generation DNA sequencing and a customized CYP2D6 genotyping cascade. J. Mol. Diagn.18(3), 438–445 (2016).
   PubMed Web of Science ®Google Scholar
• Chanfreau-Coffinier C , HullLE , LynchJAet al. Projected prevalence of actionable pharmacogenetic variants and level a drugs prescribed among US veterans health administration pharmacy users. JAMA Netw. Open2(6), e195345 (2019).
   PubMed Web of Science ®Google Scholar
• Empey PE , StevensonJM , TutejaSet al. Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin. Pharmacol. Ther.104(4), 664–674 (2018).
   PubMed Web of Science ®Google Scholar
• Lee CR , SriramojuVB , CervantesAet al. Clinical outcomes and sustainability of using CYP2C19 genotype – guided antiplatelet therapy after percutaneous coronary intervention. Circ. Genomic Precis. Med.11(4), e002069 (2018).
   PubMed Web of Science ®Google Scholar
• Mega JL , SimonT , ColletJPet al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA304(16), 1821–1830 (2010).
   PubMed Web of Science ®Google Scholar
• Cavallari LH , LeeCR , BeitelsheesALet al. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc. Interv.11(2), 181–191 (2018).
   PubMed Web of Science ®Google Scholar
• Dayoub EJ , SeigermanM , TutejaSet al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern. Med.178(7), 943–950 (2018).
   PubMed Web of Science ®Google Scholar
• Claassens DMF , VosGJA , BergmeijerTOet al. A genotype-guided strategy for oral P2Y12 inhibitors in primary PCI. N. Engl. J. Med.381(17), 1621–1631 (2019).
   PubMed Web of Science ®Google Scholar
• Scott SA , SangkuhlK , SteinCMet al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin. Pharmacol. Ther.94(3), 317–323 (2013).
   PubMed Web of Science ®Google Scholar
• Dunnenberger HM , CrewsKR , HoffmanJMet al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu. Rev. Pharmacol. Toxicol.55(1), 89–106 (2015).
   PubMedGoogle Scholar
• Cavallari LH , BeitelsheesAL , BlakeK Vet al. The IGNITE pharmacogenetics working group: an opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin. Transl. Sci.10(3), 143–146 (2017).
   PubMed Web of Science ®Google Scholar
• Lichtman JH , BiggerJT , BlumenthalJAet al. Depression and coronary heart disease recommendations for screening, referral and treatment a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation118(17), 1768–1775 (2008).
   PubMed Web of Science ®Google Scholar
• Sanchis-Gomar F , Perez-QuilisC , LeischikR , LuciaA. Epidemiology of coronary heart disease and acute coronary syndrome. Ann. Transl. Med.4(13), 1–12 (2016).
   Web of Science ®Google Scholar
• Dong OM , LiA , SuzukiOet al. Projected impact of a multigene pharmacogenetic test to optimize medication prescribing in cardiovascular patients. Pharmacogenomics19(9), 771–782 (2018).
   PubMed Web of Science ®Google Scholar
• Lee JA , LeeCR , ReedBNet al. Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients. Pharmacogenomics16(4), 303–313 (2015).
   PubMed Web of Science ®Google Scholar
• Caudle KE , DunnenbergerHM , FreimuthRRet al. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genet. Med.19(2), 215–223 (2017).
   PubMed Web of Science ®Google Scholar
• Relling MV , McDonaghE , ChangTet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for rasburicase therapy in the context of G6PD deficiency genotype. Clin. Pharmacol. Ther.96(2), 169–174 (2014).
   PubMed Web of Science ®Google Scholar
• Hicks J , SangkuhlK , SwenJet al. Clinical Pharmacogenetics Implementation Consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin. Pharmacol. Ther.102(1), 37–44 (2017).
   PubMed Web of Science ®Google Scholar
• Hicks JK , BishopJR , SangkuhlKet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin. Pharmacol. Ther.98(2), 127–134 (2015).
   PubMed Web of Science ®Google Scholar
• Bell G , CaudleK , Whirl-CarrilloMet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin. Pharmacol. Ther.102(2), 213–218 (2017).
   PubMed Web of Science ®Google Scholar
• Crews KR , GaedigkA , DunnenbergerHMet al. Clinical Pharmacogenetics Implementation Consortium Guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin. Pharmacol. Ther.95(4), 376–382 (2014).
   PubMed Web of Science ®Google Scholar
• Wilke RA , RamseyLB , JohnsonSGet al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin. Pharmacol. Ther.92(1), 112–117 (2012).
   PubMed Web of Science ®Google Scholar
• Mega JL , WalkerJR , RuffCTet al. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet385(9984), 2280–2287 (2015).
   PubMed Web of Science ®Google Scholar
• Johnson J , CaudleK , GongLet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther.102(3), 397–404 (2017).
   PubMed Web of Science ®Google Scholar
• Saito Y , StampLK , CaudleKEet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin. Pharmacol. Ther.99(1), 36–37 (2016).
   PubMed Web of Science ®Google Scholar
• El Rouby N , LimaJJ , JohnsonJA. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug Metab. Toxicol.14(4), 447–460 (2018).
   PubMed Web of Science ®Google Scholar
• Dong OM , WheelerSB , CrudenGet al. Cost–effectiveness of multigene pharmacogenetic testing in acute coronary syndrome patients after percutaneous coronary intervention. Value Health23(1), 61–73 (2020).
   PubMed Web of Science ®Google Scholar
• Hart MR , GarrisonLP , DoyleDL , JarvikGP , WatkinsJ , DevineB. Projected cost–effectiveness for 2 gene–drug pairs using a multigene panel for patients undergoing percutaneous coronary intervention. Value Health22(11), 1231–1239 (2019).
   PubMed Web of Science ®Google Scholar
• Aziz R , SteffensDC. What are the causes of late-life depression?Psychiatr. Clin. North Am.36(4), 497–516 (2013).
   PubMed Web of Science ®Google Scholar
• Jha MK , QamarA , VaduganathanM , CharneyDS , MurroughJW. Screening and management of depression in patients with cardiovascular disease JACC state-of-the-art review. J. Am. Coll. Cardiol.73(14), 1827–1845 (2019).
   PubMed Web of Science ®Google Scholar
• Smith DM , WeitzelKW , ElseyARet al. CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial. Genet. Med.21(8), 1842–1850 (2019).
   PubMed Web of Science ®Google Scholar
• Hagymási K , MüllnerK , HerszényiL , TulassayZ. Update on the pharmacogenomics of proton pump inhibitors. Pharmacogenomics12(6), 873–888 (2011).
   PubMed Web of Science ®Google Scholar
• Owusu-Obeng A , WeitzelKW , HattonRCet al. Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy34(10), 1102–1112 (2014).
   PubMed Web of Science ®Google Scholar
• Hicks JK , DunnenbergerHM , GumpperKF , HaidarCE , HoffmanJM. Integrating pharmacogenomics into electronic health records with clinical decision support. Am. J. Heal. Syst. Pharm.73(23), 1967–1976 (2016).
   PubMed Web of Science ®Google Scholar
• Moriyama B , ObengAO , BarbarinoJet al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin. Pharmacol. Ther.102(1), 45–51 (2017).
   PubMed Web of Science ®Google Scholar